Mifepristone

Mifepristone (RU486) is a progesterone receptor (PR) and glucocorticoid receptor (GR) antagonist with IC50s of 0.2 nM and 2.6 nM in in vitro assay[1].

Product Specifications

CAS Number

[84371-65-3]

Product Name Alternative

RU486; RU 38486

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; Endogenous Metabolite; Glucocorticoid Receptor; NO Synthase; Progesterone Receptor

Type

Reference compound

Related Pathways

Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Endocrinology; Cancer

Assay Protocol

https://www.medchemexpress.com/Mifepristone.html

Purity

99.83

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

C[C@@]12[C@@](C#CC)(O)CC[C@@]1([H])[C@]3([H])CCC4=CC(CCC4=C3[C@@H](C5=CC=C(N(C)C)C=C5)C2)=O

Molecular Formula

C29H35NO2

Molecular Weight

429.59

Precautions

H302, H315, H319, H335

References & Citations

[1]Jiang W, et al. New progesterone receptor antagonists: phosphorus-containing 11beta-aryl-substituted steroids. Bioorg Med Chem. 2006 Oct 1;14 (19) :6726-32.|[2]Jurado R, et al. NSC 119875 cytotoxicity is increased by mifepristone in cervical carcinoma: an in vitro and in vivo study. Oncol Rep. 2009 Nov;22 (5) :1237-45.|[3]Sharrett-Field L, et al. Mifepristone Pretreatment Reduces Ethanol Withdrawal Severity In Vivo. Alcohol Clin Exp Res. 2013 Aug;37 (8) :1417-23.|[4]Yuehua You, et al. Progesterone Promotes Endothelial Nitric Oxide Synthase Expression Through Enhancing Nuclear Progesterone receptor-SP1 Formation. Am J Physiol Heart Circ Physiol. 2020 Jul 3.